Medication Adherence, Treatment Patterns, and Dose Reduction in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone Acetate or Enzalutamide

BACKGROUND: The efficacy of and overall survival associated with metastatic castration-resistant prostate cancer (CRPC) treatments rely on patients' consistent adherence to the recommended dosage regimens. OBJECTIVES: To evaluate treatment patterns and patient adherence to abiraterone acetate o...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Am Health Drug Benefits
Hlavní autoři: Behl, Ajay S., Ellis, Lorie A., Pilon, Dominic, Xiao, Yongling, Lefebvre, Patrick
Médium: Artigo
Jazyk:Inglês
Vydáno: Engage Healthcare Communications, LLC 2017
Témata:
Clinical
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5620511/
https://ncbi.nlm.nih.gov/pubmed/28975013
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky